A Clinical Study to Evaluate the Safety and Effectiveness of Novabel Bioabsorbable Steroid-releasing Stent for the Chronic Sinusitis

Inclusion Criteria:

• Diagnose with CRS based on Chinese guidelines for diagnosis and treatment of chronicrhinosinusitis (2018), who were scheduled to undergo primary or revision bilateralESS.
• Have evidence of bilateral sinus based on computed tomographic (CT) scan (Lund-Mackay [L-M] score of <=3 on each side).
• Can understand the purpose of this study and will to join and finish all the follow upaccording to the study. Sign the ICF.

Exclusion Criteria:

1. Know history of allergy or intolerance to corticosteroids or mometasone furoate.
2. The subject has a known allergic reaction or contraindication to the device materialand its degradation products (L-polylactic acid, racemic polylactic acid, lactidelactate, lactic acid).
3. Clinical evidence of cystic fibrosis, severe polyposis or sinonasal tumors.
4. Clinical evidence of acute bacterial sinusitis or suspicion of invasive fungalsinusitis.
5. Glaucoma, ocular hypertension, posterior subcapsular cataracts.
6. Known history of immune deficiency or concurrent condition requiring activechemotherapy and/or immunotherapy management for the disease.
7. Clinical evidence of disease or condition expected to compromise survival or abilityto complete follow-up assessments during the 360 day follow-up period.
8. Current ESS including frontal sinus surgery is aborted for any reason.
9. Pregnant or lactating female
10. Investigator determination that the potential study subject is unable to comply withstudy procedures and/or follow-up, or provided informed consent.
11. Currently involved in another clinical study where that participation may conflict orinterfere with the treatment, follow-up or results of the clinical study.